AASLD Interview | Dr. Jian Wu’s Research Group at Fudan University Shanghai Medical College Shares Highlights and Insights from AASLD 2023

AASLD Interview | Dr. Jian Wu’s Research Group at Fudan University Shanghai Medical College Shares Highlights and Insights from AASLD 2023

2023.12.22
Since 1997, Professor Jian Wu's research group at Fudan University Shanghai Medical College has been actively participating in the annual meeting of the American Association for the Study of Liver Diseases (AASLD 2023). This year, the research group has had four abstracts selected for poster presentations and one abstract chosen for an oral presentation in a thematic session. The selected abstracts primarily focus on three main topics: the molecular basis of the Hedgehog signaling pathway in hepatocellular carcinoma; the molecular mechanisms of the JCAD protein in liver fibrosis and regeneration; and the mechanisms by which gut microbiota-derived metabolites promote the progression of chronic liver disease. "Hepatology Digest" had the privilege of inviting Dr. Jian Wu to the conference to discuss the research findings and their significance, share insights and advice on scientific research, and talk about the topics and experiences that caught his interest during the conference. The interview video and summaries of the five research presentations are provided below.
Multiple Studies on Antiviral Treatment for Chronic Hepatitis B Selected for Conference Exchange, with a Focus on the Stability of Decompensation

Multiple Studies on Antiviral Treatment for Chronic Hepatitis B Selected for Conference Exchange, with a Focus on the Stability of Decompensation

2023.12.22
From November 10th to 14th, 2023, the American Association for the Study of Liver Diseases (AASLD) Annual Meeting was grandly held in Boston, USA. In this event, Dr. Wen Xie's team from Beijing Ditan Hospital, Capital Medical University, presented several notable research findings. One of them is a study on the stability of decompensation in patients with chronic hepatitis B and liver cirrhosis treated with entecavir (ETV) [1], which received the Outstanding Abstract Award at the conference. Hepatology Digest reports on these research findings as follows.
Dr. Jing Zhang: Team’s 7 Achievements in the Fields of Fatty Liver, Cirrhosis, and Hepatitis C, Research Insights, and Future Directions

Dr. Jing Zhang: Team’s 7 Achievements in the Fields of Fatty Liver, Cirrhosis, and Hepatitis C, Research Insights, and Future Directions

2023.12.22
From November 10th to 14th, 2023, the American Association for the Study of Liver Diseases (AASLD) Annual Meeting 2023 was held in Boston, USA. Professor Jing Zhang and her team from Beijing Youan Hospital, Capital Medical University, have long focused on scientific research in chronic liver diseases. Seven research findings from the team were included in the conference and presented in poster form, covering non-alcoholic fatty liver disease (NAFLD) [1-3], cirrhosis [4-5], and hepatitis C [6-7]. "Hepatology Digest" had the privilege of inviting Professor Jing Zhang for an interview at the conference to introduce the research findings, share insights into clinical research, and discuss topics of interest and future research directions. The interview video and some research content are shared below.
AASLD Voice of China | Dr. Hong Tang’s Team: Multiple Research Achievements in the Fields of Hepatitis B, Hepatitis C, and Non-Alcoholic Fatty Liver D

AASLD Voice of China | Dr. Hong Tang’s Team: Multiple Research Achievements in the Fields of Hepatitis B, Hepatitis C, and Non-Alcoholic Fatty Liver D

2023.12.22
From November 10th to 14th, 2023, the American Association for the Study of Liver Diseases Annual Meeting (AASLD2023) was held in Boston, USA. Professor Hong Tang's team from West China Hospital of Sichuan University presented multiple research studies in the fields of hepatitis B, hepatitis C, and non-alcoholic fatty liver disease (NAFLD) at the conference. The research was included in the conference proceedings and presented in the form of posters. Congratulations to the team! Hepatology Digest reports on these research findings, and the relevant content is summarized below.
AASLD 2023丨Landmark Chinese Study on NASH Treatment Presented at AASLD

AASLD 2023丨Landmark Chinese Study on NASH Treatment Presented at AASLD

2023.12.22
On November 11, 2023, at the American Association for the Study of Liver Diseases annual meeting (AASLD 2023), the results of China's first international registered randomized controlled trial (RCT) evaluating therapeutic efficacy through liver histology, known as the VENS study, were showcased in poster format. This presentation garnered significant attention and discussions from international experts in liver diseases. The conference brought together leading global experts in clinical hepatology, liver transplantation, and hepatobiliary surgery to advance clinical research and practices, providing optimal treatment guidance for liver and biliary disease patients.
Focusing on Hepatitis B, New Developments in the “Oasis” Project and Exploration of TAF’s Immune Modulation Effects

Focusing on Hepatitis B, New Developments in the “Oasis” Project and Exploration of TAF’s Immune Modulation Effects

2023.12.22
The annual highlight in the field of hepatology, the 2023 American Association for the Study of Liver Diseases (AASLD) Annual Meeting, is currently taking place in Boston, USA. Two research achievements related to the treatment and management of hepatitis B by Dr. Wenhong Zhang and Dr. Jiming Zhang 's team from Huashan Hospital, affiliated with Fudan University, have been included in the conference. One is a phase analysis of the Oasis Project, a study aimed at reducing the occurrence of liver cancer in Chinese hepatitis B patients, revealing the safety and benefits of interferon application in specific populations. The other explores the immune modulation effects of tenofovir alafenamide (TAF) treatment and predictive indicators of efficacy. "Hepatology Digest" hereby reports on these findings.
Presentation of Research Achievements in Liver Transplantation and New Insights into Liver Transplantation Progress

Presentation of Research Achievements in Liver Transplantation and New Insights into Liver Transplantation Progress

2023.12.22
From November 10th to 14th, 2023, the annual grand event in the field of hepatology, the American Association for the Study of Liver Diseases Annual Meeting (AASLD2023), took place in Boston, USA. The on-site reporting team of "Hepatology Digest" had the privilege of inviting Dr. Wei Rao's team from the Organ Transplant Center of Qingdao University Affiliated Hospital, to introduce the team's achievements, share their experiences at the conference, and discuss future research directions. The interview content is shared below.
AASLD Voice of China | Dr. Liang Peng’s Team: Release of Clinical and Basic Research Results on Multiple Hepatitis B Studies, Preliminary Confirmation

AASLD Voice of China | Dr. Liang Peng’s Team: Release of Clinical and Basic Research Results on Multiple Hepatitis B Studies, Preliminary Confirmation

2023.12.22
From November 10th to 14th, 2023, the annual international highlight event in the field of hepatology, the 2023 American Association for the Study of Liver Diseases (AASLD) Annual Meeting, is being held in Boston, USA. Dr. Liang Peng's team from the Third Affiliated Hospital of Sun Yat-sen University has had multiple research results included in the conference. One randomized controlled trial evaluated the safety and effectiveness of tenofovir alafenamide fumarate (TAF) treatment for hepatitis B "healthy" carriers, and preliminary results indicate that TAF is safe for this population, with a rapid decrease in HBV DNA after 24 weeks of antiviral therapy, especially in the HBeAg-negative group where the HBV DNA undetectable rate is high [1].